Global Metachromatic Leukodystrophy (MLD) Treatment Market Insights and Forecast to 2031

Report ID: 1564025 | Published Date: Sep 2024 | No. of Page: 91 | Base Year: 2023 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Metachromatic Leukodystrophy (MLD) Treatment Product Introduction
    1.2 Market by Type
        1.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 AGT-183
        1.2.3 DUOC-01
        1.2.4 GSK-2696274
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Estimates and Forecasts 2017-2028
    2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Estimates and Forecasts 2017-2028
    2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region
        2.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2017-2022)
        2.4.2 Global Sales Metachromatic Leukodystrophy (MLD) Treatment by Region (2023-2028)
    2.5 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region
        2.5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2017-2022)
        2.5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers
        3.1.1 Global Top Metachromatic Leukodystrophy (MLD) Treatment Manufacturers by Sales (2017-2022)
        3.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment in 2021
    3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers
        3.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2017-2022)
        3.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Metachromatic Leukodystrophy (MLD) Treatment Revenue in 2021
    3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type
        4.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Sales by Type (2017-2022)
        4.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Sales by Type (2023-2028)
        4.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type
        4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Revenue by Type (2017-2022)
        4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type
        4.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2017-2022)
        4.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application
        5.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Sales by Application (2017-2022)
        5.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Sales by Application (2023-2028)
        5.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application
        5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Revenue by Application (2017-2022)
        5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application
        5.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2017-2022)
        5.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
        6.1.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
        6.1.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
    6.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
        6.2.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
        6.2.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
    6.3 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
        6.3.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
        6.3.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
        7.1.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
        7.1.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
    7.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
        7.2.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
        7.2.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
    7.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
        7.3.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
        7.3.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
        8.1.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
        8.1.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
    8.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
        8.2.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
        8.2.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
    8.3 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region
        8.3.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2017-2028)
        8.3.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
        9.1.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
        9.1.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
    9.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
        9.2.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
        9.2.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
    9.3 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
        9.3.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
        9.3.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
        10.1.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
    10.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
        10.2.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
    10.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
        10.3.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 ArmaGen Inc
        11.1.1 ArmaGen Inc Corporation Information
        11.1.2 ArmaGen Inc Overview
        11.1.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 ArmaGen Inc Recent Developments
    11.2 GlaxoSmithKline Plc
        11.2.1 GlaxoSmithKline Plc Corporation Information
        11.2.2 GlaxoSmithKline Plc Overview
        11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 GlaxoSmithKline Plc Recent Developments
    11.3 Recursion Pharmaceuticals Inc
        11.3.1 Recursion Pharmaceuticals Inc Corporation Information
        11.3.2 Recursion Pharmaceuticals Inc Overview
        11.3.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Recursion Pharmaceuticals Inc Recent Developments
    11.4 RegenxBio Inc
        11.4.1 RegenxBio Inc Corporation Information
        11.4.2 RegenxBio Inc Overview
        11.4.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 RegenxBio Inc Recent Developments
    11.5 Takeda
        11.5.1 Takeda Corporation Information
        11.5.2 Takeda Overview
        11.5.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Takeda Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Chain Analysis
    12.2 Metachromatic Leukodystrophy (MLD) Treatment Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process
    12.4 Metachromatic Leukodystrophy (MLD) Treatment Sales and Marketing
        12.4.1 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels
        12.4.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
    12.5 Metachromatic Leukodystrophy (MLD) Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
    13.2 Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
    13.3 Metachromatic Leukodystrophy (MLD) Treatment Market Challenges
    13.4 Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
14 Key Findings in The Global Metachromatic Leukodystrophy (MLD) Treatment Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of AGT-183
    Table 3. Major Manufacturers of DUOC-01
    Table 4. Major Manufacturers of GSK-2696274
    Table 5. Major Manufacturers of Others
    Table 6. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2017-2022) & (K Pcs)
    Table 9. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2017-2022)
    Table 10. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2023-2028) & (K Pcs)
    Table 11. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2023-2028)
    Table 12. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2017-2022)
    Table 14. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2023-2028)
    Table 16. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 17. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Manufacturers (2017-2022)
    Table 18. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Manufacturers (2017-2022)
    Table 20. Metachromatic Leukodystrophy (MLD) Treatment Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 21. Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Metachromatic Leukodystrophy (MLD) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metachromatic Leukodystrophy (MLD) Treatment as of 2021)
    Table 23. Metachromatic Leukodystrophy (MLD) Treatment Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Metachromatic Leukodystrophy (MLD) Treatment Product Offered
    Table 25. Date of Manufacturers Enter into Metachromatic Leukodystrophy (MLD) Treatment Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 28. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 29. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2017-2022)
    Table 30. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2023-2028)
    Table 31. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2017-2022)
    Table 34. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2023-2028)
    Table 35. Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2017-2022) & (USD/Pcs)
    Table 36. Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 37. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 38. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 39. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2017-2022)
    Table 40. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2023-2028)
    Table 41. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2017-2022)
    Table 44. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2023-2028)
    Table 45. Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2017-2022) & (USD/Pcs)
    Table 46. Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 47. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 48. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 49. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 52. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 53. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 56. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 57. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 60. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 61. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 64. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 65. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 68. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 69. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 72. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 73. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 76. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 77. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2017-2022) & (K Pcs)
    Table 80. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2023-2028) & (K Pcs)
    Table 81. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 84. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 85. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 88. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 89. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 92. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 93. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 96. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 97. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 100. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 101. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 104. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 105. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 107. ArmaGen Inc Corporation Information
    Table 108. ArmaGen Inc Description and Major Businesses
    Table 109. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. ArmaGen Inc Recent Developments
    Table 112. GlaxoSmithKline Plc Corporation Information
    Table 113. GlaxoSmithKline Plc Description and Major Businesses
    Table 114. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. GlaxoSmithKline Plc Recent Developments
    Table 117. Recursion Pharmaceuticals Inc Corporation Information
    Table 118. Recursion Pharmaceuticals Inc Description and Major Businesses
    Table 119. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 120. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Recursion Pharmaceuticals Inc Recent Developments
    Table 122. RegenxBio Inc Corporation Information
    Table 123. RegenxBio Inc Description and Major Businesses
    Table 124. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 125. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. RegenxBio Inc Recent Developments
    Table 127. Takeda Corporation Information
    Table 128. Takeda Description and Major Businesses
    Table 129. Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 130. Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Takeda Recent Developments
    Table 132. Key Raw Materials Lists
    Table 133. Raw Materials Key Suppliers Lists
    Table 134. Metachromatic Leukodystrophy (MLD) Treatment Distributors List
    Table 135. Metachromatic Leukodystrophy (MLD) Treatment Customers List
    Table 136. Metachromatic Leukodystrophy (MLD) Treatment Market Trends
    Table 137. Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
    Table 138. Metachromatic Leukodystrophy (MLD) Treatment Market Challenges
    Table 139. Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Metachromatic Leukodystrophy (MLD) Treatment Product Picture
    Figure 3. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type in 2021 & 2028
    Figure 3. AGT-183 Product Picture
    Figure 4. DUOC-01 Product Picture
    Figure 5. GSK-2696274 Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application in 2021 & 2028
    Figure 8. Hospital
    Figure 9. Clinic
    Figure 10. Others
    Figure 11. Metachromatic Leukodystrophy (MLD) Treatment Report Years Considered
    Figure 12. Global Metachromatic Leukodystrophy (MLD) Treatment Sales 2017-2028 (K Pcs)
    Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue 2017-2028 (US$ Million)
    Figure 15. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 16. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2017-2022)
    Figure 17. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2023-2028)
    Figure 18. North America Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 19. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 21. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 23. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 25. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 27. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. The Metachromatic Leukodystrophy (MLD) Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 29. The Top 5 and 10 Largest Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment in the World: Market Share by Metachromatic Leukodystrophy (MLD) Treatment Revenue in 2021
    Figure 30. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 31. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    Figure 32. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    Figure 33. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    Figure 34. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    Figure 35. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    Figure 36. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    Figure 37. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    Figure 38. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    Figure 39. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2017-2028)
    Figure 40. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2017-2028)
    Figure 41. U.S. Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 42. Canada Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 43. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    Figure 44. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    Figure 45. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    Figure 46. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    Figure 47. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2017-2028)
    Figure 48. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2017-2028)
    Figure 49. Germany Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 50. France Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 51. U.K. Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 52. Italy Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 53. Russia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 54. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Region (2017-2028)
    Figure 59. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Region (2017-2028)
    Figure 60. China Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 61. Japan Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 62. South Korea Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 63. India Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 64. Australia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 65. Taiwan Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 66. Indonesia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 67. Thailand Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 68. Malaysia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 69. Philippines Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 70. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    Figure 71. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    Figure 72. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    Figure 73. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    Figure 74. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2017-2028)
    Figure 75. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2017-2028)
    Figure 76. Mexico Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 77. Brazil Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 78. Argentina Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 79. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
    Figure 81. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
    Figure 83. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2017-2028)
    Figure 84. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2017-2028)
    Figure 85. Turkey Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 86. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 87. UAE Metachromatic Leukodystrophy (MLD) Treatment Revenue (2017-2028) & (US$ Million)
    Figure 88. Metachromatic Leukodystrophy (MLD) Treatment Value Chain
    Figure 89. Metachromatic Leukodystrophy (MLD) Treatment Production Process
    Figure 90. Channels of Distribution
    Figure 91. Distributors Profiles
    Figure 92. Bottom-up and Top-down Approaches for This Report
    Figure 93. Data Triangulation
    Figure 94. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
ArmaGen Inc
GlaxoSmithKline Plc
Recursion Pharmaceuticals Inc
RegenxBio Inc
Takeda
Frequently Asked Questions
Metachromatic Leukodystrophy (MLD) Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Metachromatic Leukodystrophy (MLD) Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Metachromatic Leukodystrophy (MLD) Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports